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Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their
inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and
the type of oral anticoagulant. Knowledge on coagulation tests applicable in monitoring status and reversal of oral
anticoagulation is a prerequisite when studying potential reversal agents or when managing anticoagulation in a
clinical setting. Specialty tests based on the measurement of residual activated factor X (Xa) or thrombin activity, e.g.,
are highly effective for determining the concentration of the new generation direct factor Xa- and thrombin inhibitors,
but these tests are unsuitable for the assessment of anticoagulation reversal by non-specific prohemostatic agents like
prothrombin complex concentrate (PCC) and recombinant factor VIIa (FVIIa). Global coagulation assays, in this respect,
seem more appropriate. This review evaluates the current status on the applicability of the global coagulation assays
PT, APTT, thrombin generation and thromboelastography in the management of oral anticoagulation by vitamin
K antagonists and the direct factor Xa and thrombin inhibitors. Although all global tests are influenced by both
types of anticoagulants, not all tests are useful for monitoring anticoagulation and reversal thereof. Many (pre)
analytical conditions are of influence on the assay readout, including the oral anticoagulant itself, the concentration of
assay reagents and the presence of other elements like platelets and blood cells. Assay standardization, therefore,
remains an issue of importance.
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With the introduction in the 1940’s of vitamin K antago-
nists (VKAs) as an oral anticoagulant drug for the treat-
ment of patients at risk for a thromboembolic event, the
need for proper coagulation testing emerged [1,2]. In the
early days of anticoagulant drug development, coagula-
tion was a simple 4-factor mechanism consisting of
thromboplastin, calcium, fibrinogen and prothrombin
[3]. The prothrombin time assay introduced by Quick
was performed in plasma taken from blood collected
into sodium oxalate and clotting was initiated by adding
calcium and thromboplastin reagent (crude tissue factor
extract) from rabbit brain [4]. Owren, with the discovery
of the clotting factors V, VII, VIII, IX, X, XI and XII,
introduced a mixture of thromboplastin, cephalin (unre-
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unless otherwise stated.and phosphatidylserine) and aluminum hydroxide-absorbed
plasma in order to make the assay more sensitive to anti-
coagulant treatment with VKAs [5]. Both methods, albeit
with better defined reagents, are still widely recommended
in guidelines on the management of oral anticoagulation by
VKAs [6-8].
The development of coagulation tests goes hand in
hand with increasing knowledge on the coagulation sys-
tem. Evolving clinical experience has made practitioners
doubting the value of the PT test in the management of
VKA anticoagulation [9-11]. Also, the introduction of a
new class of oral anticoagulants that target a specific
activated clotting factor requires re-evaluation of the
usefulness of the PT in the management of oral anti-
coagulation. Recent guidelines already suggest the use
of thromboelastography in the management of VKA
anticoagulation [12]. Thrombography, for which point
of care tests are currently being developed, will soon fol-
low [13]. However, these assays are complex and thereforeis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Knowledge on the assay principles as well as on the
mechanism of action of the anticoagulant and its
reversal agent is inevitable related to an adequate use
of global assays in anticoagulation management. The
wide variety of global assay and reagents available
underscores the need for standardization and assay valid-
ation. In this review, a comparison is made between VKAs
and direct thrombin and factor Xa inhibitors with respect
to assay sensitivity and laboratory monitoring options for
the control of anticoagulation reversal by non-specific
hemostatic agents.
Oral anticoagulants and reversal agents
Vitamin K antagonists
The history of oral anticoagulation starts in 1939 with the
isolation of Dicoumarol. This drug became the prototype
of a variety of orally administered coumarin derivatives
with anticoagulant properties such as warfarin and phen-
procoumon [14-16]. Coumarins, also known as vitamin K
antagonists (VKAs), act by inhibiting the enzyme vitamin
K reductase. During the post-translational carboxylation
of vitamin K-dependent procoagulant factors II, VII, IX, X,
as well as the natural vitamin K-dependent anticoagulant
protein C and protein S by gamma-glutamyl-carboxylase,
vitamin K removes hydrogen atoms from glutamic acid
residues. Vitamin K than collapses into vitamin K epoxide
and is recycled back to active vitamin K following the
action of vitamin K reductase [17]. By inhibiting vitamin K
reductase, the carboxylation process is downscaled. This
results in the synthesis of vitamin K-dependent clotting
























Figure 1 Oral anticoagulation; mechanism and site of action.(Gla) residues and hence with severely hampered binding
properties to negatively charged surfaces (Figure 1). Bind-
ing of vitamin K-dependent clotting factors to negatively
charged phospholipids is a necessity to facilitate hemostasis
[18]. VKAs are anticoagulant because they suppress the syn-
thesis of functionalmembrane-binding clotting factors.Reversal of vitamin K antagonist-induced anticoagulation
A major complication with the use of VKAs is bleeding.
The widespread use of VKAs in clinical practice, there-
fore, is just a matter of statistics: the number of people
that is protected from major thrombotic complications
is greater than the number of people showing VKA-
associated bleeds [19]. Furthermore, clinicians have
VKA-reversal agents at their disposal. First in line is
vitamin K, suppressing the action of coumarins. De-
novo synthesis of vitamin K-dependent clotting factors,
however, may take too long. For immediate emergency re-
versal, replenishment of functional vitamin K-dependent
clotting factors seem more appropriate [6,7]. This can be
achieved by intravenous administration of 4-factor pro-
thrombin complex concentrate (PCC), consisting of
plasma derived human prothrombin, factor VII, factor IX
and factor X. It should be noted that most PCCs also
contain the vitamin K-dependent coagulation inhibitors
protein C and protein S and in addition are supple-
mented with antithrombin and/or heparin [20]. The
use of fresh frozen plasma, three-factor PCC (lacking
factor VII) and recombinant factor VIIa as reversal
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When using VKAs and apart from the increased bleed-
ing risk, the following drawbacks need to be considered:
slow onset and slow offset, more than 120 known food
and drug interactions, requirement for regular monitor-
ing [21]. These disadvantages of VKAs has led to the de-
velopment of oral anticoagulant drugs that directly
target activated factor X and thrombin (Figure 1). These
novel oral anticoagulants (NOACs), also addressed as
direct oral anticoagulants (DOACs), target specific oral
anticoagulants (TSOAs) or non-vitamin K antagonist
oral anticoagulants (NOACs), are small synthetic com-
pounds that reversibly bind to the active site of factor
Xa or thrombin [22-27]. To date, three NOACs have
been approved for use in specific patients groups: the
factor Xa inhibitors apixaban and rivaroxaban and the
thrombin inhibitor dabigatran [28].
Reversal of non-vitamin K antagonist oral anticoagulation
Reversal agents that specifically target NOACs are under
development and presently unavailable for general clin-
ical use [29,30]. Current guidelines unanimously suggest
the use of PCC as first in line drug in emergency situa-
tions with direct factor Xa inhibitor-associated bleeds
but these guidelines are contradictory with regard to re-
versal of anticoagulation by dabigatran [8,12,28,31]. Re-
combinant activated factor VII (rFVII) and activated
factor VII-containing PCC (activated PCC), agents that













Figure 2 Coagulation pathways implicated in intrinsic (contact activatio
highlighted targets for oral anticoagulation. Cofactors V and VIII are indica
procoagulant factors, targets for VKA anticoagulation. Black circles indicate the
triangle shows the target for the direct thrombin inhibitor dabigatran. Specific
tissue factor (TF) concentration. At high TF concentrations, enough factor X is
factor VIII is negligible. At low TF concentrations (<5 pM), extrinsic based assay
feedback activation of factor XI by thrombin (IIa), allowing factor XI to be invo
factor concentration (≤1 pM). Θ, negatively charged surface, e.g. celite or kaolhemophilic patients with inhibitors, may also be of po-
tential use [8,12,28,31]. Mechanism of action of PCC in
the reversal of NOAC anticoagulation differs from that
in VKA reversal. With respect to VKA reversal, PCC re-
plenishes the level of functional vitamin K dependent
clotting factors. With regard to NOAC reversal, func-
tional clotting factors already are present and reversal of
NOAC anticoagulation by PCC most likely is due to an
increased number of factor Xa or thrombin molecules
escaping from inhibition [32]. A similar model may also
be applicable for rFVIIa and activated PCC, clotting fac-
tor concentrates just as PCC able to increase thrombin
generation when added to normal plasma [33,34]. In
addition, rFVII may also improve platelet deposition at
sites of vessel trauma [35].
Global coagulation assays
Clotting time
Global tests, in contrast to assays specific to individual
clotting factors, provide an overall assessment of the
functioning of the coagulation system. Coagulation in
global tests is triggered either by agents that contain
negatively charged particulate (kaolin, silica, ellagic acid,
celite) to initiate contact activation (intrinsic pathway),
or by reagents that contain tissue factor (TF) to initiate
the extrinsic pathway (Figure 2). The most widely used
global coagulation test is the clotting time. Triggered
with TF, this assay is known as the prothrombin time















n, CA) - and extrinsic (tissue factor, TF) based global assays with
ted in their activated forms. Grey squares indicate vitamin K-dependent
target for direct factor Xa inhibitors, i.e. rivaroxaban and apixaban. Black
ity and sensitivity of extrinsic pathway based assays is determined by the
activated directly by TF/VIIa and hence the contribution of factor IX and
s are also sensitive to factor VIII and IX. Dotted arrowed line indicates
lved in the extrinsic pathway but this is noticed only at very low tissue
in, facilitating contact activation. Fbg, fibrinogen. Fb, fibrin.
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plastin time (APTT). This nomenclature is from histor-
ical origin. The PT test was developed in the beginning
of the last century when all clotting factors except pro-
thrombin still had to be discovered. Triggering reagent
is thromboplastin, a term originally used to describe a
substance in plasma that converts prothrombin to
thrombin [4]. Historically, thromboplastins were ex-
tracted from brain and other organs and these extracts
contained significant amounts of TF and phospholipid.
The term “partial” in APTT refers to reagents without
TF, while “activated” refers to the use of negatively
charged particulate contact activators to improve re-
sponsiveness and reproducibility [36].
The PT and APTT are performed with citrated platelet
poor plasma to which calcium and trigger reagent is
added. With these tests, the time is recorded until a vis-
ible clot is formed. In the PT according to the Quick
method [4] as well in the APTT, undiluted test plasma is
used. In the PT following the Owren method [5], test
plasma is diluted with absorbed bovine plasma as source
of factor V and fibrinogen. A wide variety of thrombo-
plastins with inconsistent clotting activity has led to the
introduction of the international normalized ratio (INR)
that aims to harmonize PT results obtained with VKA-
anticoagulated plasma regardless of the reagent and in-
strument used [37]. The APTT is sensitive to deficiencies
in all clotting factors implicated in the intrinsic pathway
(Figures 2 and 3). Clotting factor sensitivity of the PT by
design is downscaled to fibrinogen and the factors II (pro-
thrombin), V, VII and X. Due to high TF concentrations in
the triggering reagent, the PT is insensitive to factor VIIIFigure 3 Clotting factor sensitivity of different global coagulation
assays. This figure shows the sensitivity of global tests for clotting factor
deficiencies. A mark indicates that an assay is highly sensitive (green),
moderate sensitive (blue), or slightly sensitive (orange) to the absence
(<1%) of a certain clotting factor. No mark indicates no sensitivity, i.e. a
normal assay readout. Sensitivity of different global coagulation tests for
deficiencies in procoagulant factors are based on data provided in the
following publications: clotting time based PT and APTT [38,39],
thrombin generation assay (TGA) [40], thromboelastography (TEG) [41].
The presence of factor V in the assay reagents makes the Owren PT
insensitive to this coagulation factor. *0.1% rabbit brain thromboplastin.
**Negatively charged particulate to initiate contact activation.and factor IX (Figures 2 and 3). The Owren method, in
contrast to the Quick method, is also insensitive to
fibrinogen and factor V, as these compounds are present
in the supplied reagents.
Drawback of the PT and APTT is that it measures the
clotting time only. Once a visible clot is formed, throm-
bin and fibrin formation proceeds until a clot with max-
imal firmness is produced and the coagulation process is
inhibited [42,43]. PT and APTT thus do not record pro-
cesses beyond initial clotting. Another drawback of the
PT and APTT is the lack of cellular contributions to
fibrin network formation [44]. These drawbacks are
challenged by more advanced global assays including
thromboelastography/thromboelastometry and the throm-
bin generation assay.
Thromboelastography/thromboelastometry
Thromboelastography (TEG) or thromboelastometry
(TEM) measures the mechanical resistance of an indica-
tor rod in clotting whole blood or plasma. Depending
on the type of equipment, either the indicator rod
(ROTEMW) or the cup containing the whole blood or
plasma (TEGW) is continuously twisting left and right
during analysis. As a consequence of fibrin formation,
viscoelasticity of the whole blood or plasma will increase
in time with concomitant increase in mechanical friction
on the indicator rod. Rephrased, thromboelastography
measures the formation (and degradation) of a fibrin clot
in time in whole blood or plasma. Parameters derived
from TEG/TEM tracings include reaction time (R) or
clotting time (CT) defined as the period to 2 mm ampli-
tude, kinetics (K) or clot formation time (CFT) being the
period from 2–20 mm amplitude, angle (A) being the
slope of the tracing, and maximum amplitude (MA) or
maximum clot firmness (MCF) [45]. With this tech-
nique, both intrinsic and extrinsic coagulation triggers
can be applied (Figures 2 and 3).
Thrombin generation assay
Of enormous edifying value is the measurement of active
thrombin in clotting plasma over time. This technique is
called thrombography and utilizes thrombin sensitive
fluorogenic or chromogenic peptide substrates [46].
These synthetic substrates, however, are cleaved by both
free thrombin and alpha-2-macroglobulin bound throm-
bin, as such overestimating the thrombin generating po-
tential of the plasma sample [47]. The algorithm that is
used in the calibrated automated thrombography (CAT)
method, corrects for the activity of alpha-2-macroglobulin
bound thrombin [48,49]. Advantage of fluorogenic sub-
strates over chromogenic substrates is that inhibition of
fibrin polymerization is not required. The thrombin gener-
ation assay (TGA) is flexible by design and allows modifi-
cations with respect to coagulation triggering reagents,
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platelets. Of innovative importance is thrombin generation
in whole blood [13]. Parameters derived from thrombo-
graphy include lag time, peak height and area under the
curve (AUC) or extrinsic thrombin potential (ETP).
Effect of old and novel oral anticoagulants on global
assays
Influence of VKAs on global assays
VKA anticoagulation will affect any global assay that is
dependent on functional vitamin K-dependent coagulation
factors (Figure 2). Influence of VKAs on global assays,
therefore, is not restricted to the for VKA monitoring gen-
erally applied PT test. Outcome of APTT, TGA and TEG/
TEM testings are affected by VKAs as well (Table 1). Sen-
sitivity of the different global tests, however, is greatly
dependent on the coagulation trigger of choice as well as
on the trigger concentration. E.g., the contact activation-
triggered APTT, in general, is less sensitive to VKA treat-
ment than the TF-triggered PT test [50,51]. Whole blood
point of care PT devices may generate a slightly increased
outcome as compared to standard laboratory PT assays in
plasma, a phenomenon that may relate to the chemistry
used (Owren or Quick based) and the presence of blood
cells and platelets [52-54].
An example of the effect of different TF concentrations
on the thrombographic analysis of VKA-anticoagulated
plasma is shown in Figure 4. At increasing TF, thrombin
generation increases; i.e. shorter lag time and increased
peak height and AUC. At a TF concentration of 1 pM,
thrombin generation in VKA-anticoagulated plasma is
often unnoticed while detectable at 5 and 20 pM. In TGA,Table 1 At a glance: global assay response to anticoagulation
Assay Parameter Oral anticoagul
VKA
PT-Quick Clotting time ↑
PT-Owren Clotting time ↑
APTT Clotting time ↑









Qualitative comparison of the effect of NOACs on global testing parameters. PT, AP
performed in citrated whole blood. Assay parameter is significantly increased (↑) or
Classifications are based on the following publications: VKA [55-59], apixaban [32,35
kaolin or celite. Global assays are sensitive to oral anticoagulation by VKAs, dire
assays, in general, do not show specificity to a particular drug. They are only difa TF concentration of 5 pM or higher is generally prac-
ticed when monitoring VKA anticoagulation [55,56,75].
The TF concentration in the for management of VKA-
anticoagulation commonly used PT test is much higher
(>1 nM). Major advantage of using a low 1 pM concen-
tration of TF is the gained or increased sensitivity to
factor IX, protein Z and tissue factor pathway inhibitor
(TFPI), proteins to be held responsible for the failure of
the INR to adequately reflect the anticoagulant state in
some individuals on VKA [76-78]. Of importance is
whether thrombomodulin (TM) is present during analysis.
TM is a component of the vascular wall and essential for
the generation of activated protein C and concomitant
functioning of the protein C/S anticoagulant pathway. For
TGA it has been concluded that in the absence of TM,
thrombin generation in VKA anticoagulated plasma is
overestimated [79].
Controversial data have been reported regarding the
applicability of the TEG/TEM in monitoring VKA treat-
ment. Reports have shown very poor sensitivity of the
whole blood TEG towards VKA treatment and TEG out-
come was normal in a considerable amount of VKA pa-
tients despite an increased PT (INR 1.5-2.8) [57,58]. In a
study among healthy volunteers, however, both PT/INR
and TEG readout was substantially altered upon VKA
treatment [59].
In summary, the PT/INR remains the test of choice for
monitoring VKA anticoagulation. APTT in general is less
sensitive to VKA treatment than the commonly applied
PT and is not recommended. Applicability of the TEG/
TEM in the management of oral anticoagulation by VKAs















TT and TGA assays were performed in citrated plasma. TEG/TEM assays were
decreased (↓) by the oral anticoagulant, or effect is marginal to unnoticed (−).
,60-63], rivaroxaban [62-69], dabigatran [32,56,63,69-74]. *Contact activator
ct factor Xa inhibitors and direct thrombin inhibitors. Global coagulation
ferent in drug sensitivity (see Table 2).









































































































Figure 4 Influence of TF concentration on the thrombographic assessment of oral anticagulation. Thrombin generation with VKA anticoagulated
plasma (George King Biomedical Inc, Overland Park, Kansas, USA ) and rivaroxaban-spiked normal plasma was performed with triggering
reagent containing 4 μM phospholipids and 1, 5, and 20 pM TF as described [68]. At decreasing TF, thrombin generation decreases; i.e. longer
lag time and decreased peak height and AUC. At a TF concentration of 1 pM, thrombin generation in VKA- and rivaroxaban anticoagulated
plasma is unnoticed at high anticoagulant levels, while detectable at 5 and 20 pM. Reversal of oral anticoagulation can be achieved, e.g., by
PCC (see Figure 6).
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ising but requires validation and standardization.
Influence of NOACs on global assays
NOACs may affect any assay that depends on factor Xa
or IIa (thrombin) activity, including the PT, APTT,
TGA and TEG/TEM (Figure 2). Effect of NOACs on
global tests have been shown in several publications
[32,60-68,70-72,80]. However, experimental conditions,
used tests and reported output parameters vary
between the different studies, allowing only a qualita-
tive comparison of published data between different
NOACs and the different global tests (Table 1). A detailed,
quantitative in vitro comparison between the effect of
apixaban, rivaroxaban and dabigatran on different global
tests performed with platelet poor plasma under identical
experimental conditions is shown in Table 2. For rivaroxa-
ban, examples showing dose–response relationships in PT,
TGA and TEG are shown in Figure 5.
PT and APTT, as well as other global tests, do not show
specificity to a particular drug. They are only different in
drug sensitivity. PT and APTT show poor sensitivity to
apixaban, while significantly affected by rivaroxaban
and dabigatran (Table 2). For these two drugs, concen-
trations >200 μg/L were required to increase the clotting
time by 50%. This suggests that a significant change in PTand APTT is only achieved at relatively high drug levels.
Indeed, PT and APTT are often normal in patients on
therapeutic doses of rivaroxaban and dabigatran [86,87].
Of importance is the extent by which the plasma sample is
diluted when performing a PT; typically 3 fold with the
Quick method and 20 fold when performing a PT accord-
ing to the method of Owren. A more diluted sample with
the Owren method will result in lower NOAC levels dur-
ing PT measurements. The PT test according to Owren,
therefore, is often less sensitive to NOACs as compared to
the Quick method [61,65,88-90]. Strongly approved sensi-
tivity with an effective concentration within the clinical
therapeutic dose range for all NOACs, including apixaban,
was observed with a modified PT (mPT) reagent consisting
of thromboplastin diluted with CaCl2 (Table 2, Figure 5).
The non-linear dose–response relationship as observed for
rivaroxaban with mPT but also with standard PT reagents,
is usually much less prominent for apixaban and dabiga-
tran. Another issue of importance is standardization, given
the high variability in NOAC response between different
thromboplastin reagents (Table 2 [61,64-66,70,88,90,91]),
an essential aspect when applying the PT test to NOAC
monitoring. For VKA anticoagulation, it is general practice
to normalize PT outcome to INR using an international
sensitivity index (ISI) supplied by the manufacturer of the
used thromboplastin reagent. ISI values for VKA-
Table 2 In detail: NOAC sensitivity of different global coagulation tests in plasma
Rivaroxaban Apixaban Dabigatran
In vivo therapeutic dose1
Acute VTE: 15 mg bid 10 mg bid 150 mg bid
Prophylaxis: 20 mg od 5 mg bid 150 mg bid
In vivo mean plasma concentration (Cmin-Cmax, μg/L)1
Acute VTE: 100 - 270 104 - 330 93 - 184
Prophylaxis: 45 - 250 50 - 128 93 - 184
In vitro effective concentration (μg/L)2
PT – Innovin 399 ± 49 >800 596 ± 73
– Thromborel 392 ± 36 >800 554 ± 41
– Neoplastin 214 ± 36 >800 538 ± 47
modified PT – mPT-Innovin 43 ± 3 190 ± 13 64 ± 6
– mPT-Thromborel 47 ± 3 80 ± 6 88 ± 10
APTT – Actin FSL 254 ± 28 >800 190 ± 15
TGA – Lag time 41 ± 5 93 ± 28 27 ± 7
– Peak thrombin 109 ± 5 121 ± 4 380 ± 71
– AUC 151 ± 36 327 ± 99 433 ± 71
TEG-TF – R 28 ± 3 80 ± 17 16 ± 8
– Angle 263 ± 66 721 ± 73 484 ± 3
– MA >800 >800 >800
1NOAC dose (od, once daily; bid, twice daily) currently advised for the treatment of acute venous thromboembolism (VTE) and the prophylactic treatment of VTE
and atrial fibrillation [81,82] with mean NOAC concentration in plasma at steady state during treatment pre dose (Cmin) and 2 h post dose (Cmax) [83-85].
2Pooled normal citrated plasma was spiked with NOACs ranging from 0–800 μg/L plasma and subjected to PT APTT, TGA and TEG analysis. The modified PT (mPT)
reagent consisted of a mixture of 1 volume thromboplastin reagent and 1.25 volumes 80 mM CaCl2 [85]. The TGA assay was with 5 pM TF and 4 μM
phospholipids. The TEG-TF in plasma was with 10 pM TF and 4 μM phospholipids. Effective concentration (EC±50%) was defined as a 50% increase or decrease in
assay parameter by the NOAC of interest as compared to incubations without NOAC. EC±50% values were obtained by interpolation and are given as mean ± SD of
at least 3 determinations with the same plasma pool. Part of the data were taken from Dinkelaar et al. and detailed methods can be found in that study [32].
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between-thromboplastin variability in response to NOACs
and thus do not apply to NOAC-anticoagulated plasma
[90-92]. For each NOAC, separate ISI values need to be
established [93,94].
Explaining the effect of NOACs on TGA requires
some background information regarding coagulation
pathways. During the initiation phase of coagulation,
thrombin generation is primarily dependent on the
concentration of the TF/FVIIa complex [95] and thus
on feedback activation of factor VII by coagulation pro-
teases including factor Xa and thrombin [96]. During
the propagation phase, in which the bulk of thrombin
is generated, thrombin generation is predominantly
dependent on the concentration of factor Xa [95]. This
might suggest that direct Xa inhibitors affect both initi-
ation phase (TGA lag time) and propagation phase
(TGA peak and AUC) while direct thrombin inhibitors
only affect the initiation phase. On the other hand, dir-
ect thrombin inhibitors will inhibit feedback activationof factors V and VII in the initiation phase, thereby
determining the amount of factor Va/Xa complexes
available for thrombin generation in the propagation
phase. In TGA, therefore, all parameters are affected by
direct factor Xa inhibitors as well as by direct thrombin
inhibitors (Tables 1 and 2).
Complicating factor in TGA is that direct thrombin
inhibitors not only interact with free thrombin, but also
with thrombin in complex with alpha-2-macroglobulin.
The CAT method corrects for the activity of alpha-2-
macroglobulin-bound thrombin, but the used algorithm
does not take into account that thrombin bound to
alpha-2 macroglobulin also is inhibited. This results in a
small (±10%) but significant, albeit artificial, increase in
AUC and thrombin peak at low (<100 nM) plasma con-
centrations of a direct thrombin inhibitor when applying
this method [97]. Lag time does not show this artifact.
Direct thrombin inhibitor-induced hypercoagulability has
also been noticed as the consequence of reduced protein
C anticoagulation, a feature predominantly observed in the
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Figure 5 Influence of rivaroxaban on PT, TEG and TGA. Normal plasma spiked with increasing rivaroxaban concentrations was subjected to PT, TEG
and TGA measurements as described [32,68]. PT reagents Neoplastin and Innovin are commercially available from Diagnostica Stago (Asnieres sur Seine,
France) and Siemens Healtcare Diagnostics (Marburg, Germany) respectively. The modified PT (mPT) reagent was prepared by mixing 1 volume
Thromborel S (Siemens Healthcare Diagnostics) with 1.25 volumes 80 mM CaCl2. TEG was with 4 μM phospholipids (Rossix AB, Mölndal, Sweden) and 10
pM TF (Innovin, Diagnostica Stago). TGA was with the CAT reagents from Thrombinoscope (Maastricht, The Netherlands) and includes the PPP reagent
(4 μM phospholipids/5 pM TF). TEG and TGA filled grey curves: normal plasma, solid black lines: increasing dabigatran concentration. Correlations between
rivaroxaban dose and assay outcome were used to calculate the effective rivaroxaban concentration in a particular test. The mPT, TEG-R and
TGA-lag time appeared most sensitive to rivaroxaban (see Table 2).
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aware of the fact that with CAT, the calibrator (alpha-2-
macroglobulin-thrombin complex) also is inhibited by
direct thrombin inhibitors. For plasma samples that
contain a direct thrombin inhibitor, it is advisable,
therefore, to use normal plasma for calibration.
A major determinant of the NOAC effect in TF-triggered
assays such as the TGA is the tissue factor concentration
(Figure 4) [32,56,68]. At high TF (>5 pM), maximal levels of
factor Xa and thrombin are generated with significant num-
ber of factor Xa or thrombin molecules escaping from in-
hibition by NOACs. At low TF (<5 pM), thrombin
generation is tempered with probably less factor Xa or
thrombin molecules escaping from NOAC inhibition.
TEG in platelet poor plasma and triggered with 10 pM
TF showed responsiveness of the output parameters R-
time and angle to rivaroxaban, apixaban, as well as dabiga-
tran. Maximal amplitude was not affected by the NOACs.
R-time was the most sensitive parameter, revealing effect-
iveness in the therapeutic dose range for all three NOACs
(Table 2). In the whole blood TEM with standard reagents
(EXTEMW, INTEMW), only the clotting time is affected to
some extent [32]. When applying in a clinical setting, a
modified whole blood TEG/TEM with very low TF or a
TEG/TEM without TF or kaolin/celite seems more appro-
priate but this requires further validation [64,72,99]. Of
importance is the notion that whole blood assays are af-
fected by NOACs to a lesser extent than assays in platelet
poor plasma. E.g., the dabigatran dose needed to double
R-time in TEG triggered with 10 pM TF was 43 μg/l inplatelet poor plasma as compared to 187 μg/l in whole
blood [32]. A similar observation was made with TEG for
apixaban [32] and for rivaroxaban in TGA [68].
Thus, although all global assays are affected by all
NOACs (Table 2), applicability of these tests in monitoring
NOAC treatment is limited. Due to low assay sensitivity,
the PT, APTT, TGA-peak, TGA-AUC and TEG/TEM-
angle may only be suitable for detecting anticoagulation at
supratherapeutic NOAC plasma levels. The mPT, TGA-
lag time and TEG-R, assayed in platelet poor plasma, may
be the only generally applicable parameters in clinical
practice when anticoagulation monitoring is required, but
this needs further exploration.
Global assays and procoagulant treatment
Assessment of anticoagulation reversal
As some global assay parameters show good responsive-
ness to oral anticoagulants, these parameters may be useful
in the assessment of anticoagulation reversal. From a his-
torical perspective, oral anticoagulation as well as the effect
of reversal agents is monitored by PT. For VKA anticoagu-
lation this might be valid. However, the introduction of
NOACs requires the re-evaluation of currently applicable
global assays. In Figure 6, the reversal of VKA anticoagula-
tion (INR 3.6) by PCC is compared with that for rivaroxa-
ban (200 μg/l) in PT, APTT, TGA and TEG. At first glance
it can be observed that in all assays VKA anticoagulation is
completely reversed by PCC, while the reversal effect of
PCC on rivaroxaban anticoagulation is less pronounced.
















































































































Figure 6 In vitro reversal of VKA- and rivaroxaban anticoagulation by PCC. VKA anticoagulated plasma (George King Biomedical Inc) and
normal plasma anticoagulated with 200 μg/L rivaroxaban was spiked with increasing PCC dose (4-factor PCC, Cofact, Sanquin, Amsterdam, The
Netherlands). APTT, PT, TEG and TGA was performed as described [32,68]. APTT was with reagent Actin FSL from Siemens Healthcare Diagnostics.
PT was with Innovin (Siemens). The modified PT (mPT) reagent was prepared by mixing 1 volume Thromborel S (Siemens Healthcare Diagnostics)
with 1.25 volumes 80 mM CaCl2. TEG was with 4 μM phospholipids (Rossix AB) and 10 pM TF (Innovin, Diagnostica Stago). TGA was with 4 μM
phospholipids and 5 pM TF (PPP reagent, Thrombinoscope). Filled grey TGA and TEG curves: normal plasma, filled black curves: anticoagulated
plasma without spiked PCC, dotted lines: anticoagulated plasma with increasing PCC dose (0, 0.25, 0.5, 1, 2 IU/ml). Remarkable feature for NOAC
reversal is that the response to PCC is strongly TF concentration dependent; at a high TF concentration, less PCC is needed to restore TGA-peak
and TGA-AUC [32,68]. 1 IU/ml PCC ≈ 40 IU per kg body weight.
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(Table 2), do not show complete correction by PCC. The
only assay parameter for which complete normalization of
rivaroxaban (200 μg/l) anticoagulation by PCC was ob-
served was the TGA-AUC (Figure 7).
In VKA-anticoagulated plasma, complete correction of
all global assay readout parameters by PCC as observed in
Figure 6 was expected to take place on the basis of Figure 2
due to replenishment of functional vitamin K-dependent
coagulation factors. Mechanisms implicated in the influ-
ence of clotting factor concentrates on global assay read-
out parameters in NOAC anticoagulated plasma, however,
are complex and difficult to predict (discussed in: [32]).
Carefully performed feasibility studies, therefore, are es-
sential before applying global assays in clinical practice. In
vitro spiking experiments, in which both NOAC and re-
versal agent are added to normal whole blood or plasma
in a controlled setting, as in Figure 6, are ideal for this pur-
pose [32,35,68,100]. Ex vivo reversal studies, using whole
blood or plasma from anticoagulated patients or healthy
volunteers, may also be appropriate [101-103]. See Figure 8for an overview of the currently available data on this mat-
ter. What became clear from this limited number of stud-
ies is the variability in assay readout between different
NOACs and reversal agents. With PCC, e.g., partial cor-
rection of TGA-peak was observed for rivaroxaban and
apixaban, while complete parameter correction was ob-
served with dabigatran [32,68]. Similarly, complete correc-
tion of the PT by PCC was observed for apixaban while
PT correction was only partial for rivaroxaban and dabiga-
tran [32,68]. The APTT was insensitive to NOAC reversal
by PCC, while partly corrected by rFVIIa and activated
PCC [102]. The Figure 8 summary also suggests general
applicability of the TGA-AUC in monitoring NOAC re-
versal by PCC as well as by activated PCC (FVIIa contain-
ing PCC). TGA-AUC was not affected by rFVIIa. For this
reversal agent, TGA-lag time seems to be the best option.
In summary, the PT/INR remains the assay of choice
to monitor reversal of VKA anticoagulation. TGA and
TEG/TEM may be useful in this respect, but this needs
further exploration. TGA-AUC may be general applic-
able in monitoring NOAC reversal by PCC and activated



















Figure 7 Monitoring in vitro reversal of VKA- and rivaroxaban
anticoagulation with TGA-AUC. VKA plasma (INR 3.6, George
King Biomedical Inc) and rivaroxaban-anticoagulated plasma spiked
with increasing PCC dose (4-factor PCC, Cofact, Sanquin) was
subjected to TGA (4 μM phospholipids and 5 pM TF as described
[32,68]. TGA-AUC is expressed as % of not anticoagulated normal
plasma without PCC. Correlation between PCC and TGA-AUC is
more or less linear for VKA while less steeper and decaying for
rivaroxaban. For apixaban and dabigatran, similar decaying curves
were observed [32]. A decaying curve results in PCC incapable in
restoring TGA-AUC to normal at high to extreme NOAC levels. This
figure also shows that the suggested PCC dose for treatment of
rivaroxaban-associated bleeds of 50 IU per kg body weight
(±1.25 IU/ml) [12] is able to fully normalize the TGA-AUC at
200 μg/L rivaroxaban and to achieve almost complete TGA-AUC
normalization at 500 μg/L.
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blood or plasma with APTT, PT, TEG/TEM (TF-triggered) and TGA (TF-trigge
reversal with plasma from NOAC treated healthy volunteers. 2Perzborn et a
reversal with plasma and whole blood from NOAC treated patients. 4Kho
patients. 5Dinkelaar et al. [32,68], in vitro spiking experiments. 6Escolar et
presented in this review. Ex vivo reversal studies with NOAC-treated patients a
from the same patient not treated with NOAC. Ex vivo reversal in patients, if p
marks), in vitro spiking studies and ex vivo reversal studies with healthy volunte
of anticoagulation.PCC, but not by rFVIIa. TGA-lag time seems the most
appropriate assay readout for the assessment of NOAC
anticoagulation by rFVIIa, but again, this needs further
validation.
(Pre)analytical conditions that affect the assessment of
NOAC reversal
Monitoring in vivo NOAC reversal by non-specific prohe-
mostatic agents (PCC, activated PCC, rFVII) remain a
controversial issue, this despite growing evidence that
these non-specific reversal agents are able to correct, at
least in part, NOAC-induced hemorrhage (reviewed in:
[28,104,105]). In rivaroxaban-anticoagulated human vol-
unteers, e.g., the PT normalized completely upon treat-
ment with PCC [106]. In contrast, PT correction was only
partial in rivaroxaban-anticoagulated animals receiving
PCC [107,108]. In PT, extent of reversal is dependent on
NOAC concentration, NOAC type, PCC dose and used
thromboplastin reagent [32,68]. These variabilities make it
extremely difficult to compare PT outcome from different
in vivo reversal studies.
When applying TGA-AUC as readout parameter for
NOAC reversal by PCC, several analytical considerations
must be taken into account. E,g., the correlation between
TGA-AUC and PCC dose is non-linear and for rivaroxa-
ban the curves are less steeper and show faster decay
than for VKA (Figure 7). This decaying relationship was
also observed for apixaban and dabigatran and confirm
results from an earlier study on rivaroxaban [32,68]. At
very high NOAC concentration (e.g. at 800 μg/l rivarox-
aban in Figure 7), this non-linear relationship may result
in an AUC never reaching 100%. Pertinent to this viewPCC and rFVIIa. Data on in vitro NOAC reversal in human whole
red) were from the following studies: 1Marlu et al. [101], ex vivo
l. [100], in vitro spiking experiments. 3Herrmann et al. [102], ex vivo
o et al. [103], ex vivo reversal with plasma from NOAC treated
al. [35], in vitro spiking experiments. 7Additional in vitro data
re difficult to interpret due to lack of a reliable reference point, i.e. plasma
resent, is therefore classified as partial. In the overall classification (colored
ers are dominators. Most readout parameters only show partial reversal
Table 3 Applicability of laboratory assays in the





Anti-coagulation Reversal Anti-coagulation Reversal
Global assays
APTT P1 P1 P1 N2
PT/INR A A P1 P3,4
TEG/ROTEM Q3 Q3 P1 P3
TGA A3 A3 P1 P3,4
Specialty
assays
ECT/TT N2 N2 A N2
Xa-i/DTI N2 N2 A N2
A, applicable.
P, partly applicable; use with caution.
Q, questionable.
N, not applicable.
1moderate to low sensitivity.
2no sensitivity.
3requires further validation and standardization.
4assay normalization depends on NOAC type, NOAC concentration, TF
concentration and used thromboplastin reagent.
This table summary clearly shows that the applicability of a particular test in
monitoring NOAC or VKA anticoagulation does not translate directly to
applicability in reversal assessment. The PT remains the appropriate test when
managing VKA anticoagulation. TGA may also be suitable, but this requires
further validation. Specialty assays suited for NOAC monitoring (ecarin clotting
time, ECT; thrombin time, TT; direct thrombin inhibitor assay, DTI; chromogenic
factor Xa inhibitor assay, Xa-i) do not apply to reversal assessment. Monitoring
NOAC reversal is feasible with PT, TEG/ROTEM and TGA. However, most readout
parameters only show partial NOAC reversal. Global assays, in general, show low
sensitivity to NOACs (see Table 2).
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showing normalization of TGA-AUC at low (200 μg/l)
but not at high (1000 μg/l) dabigatran levels [73].
Another complicating factor in monitoring reversal of
NOAC anticoagulation by TGA is that the amount of
PCC required for AUC normalization depends on the in
the assay used TF concentration. For rivaroxaban e.g., at
1 pM TF, TGA-AUC was reduced to 11% of normal by
200 μg/l rivaroxaban and PCC up to 4 IU/ml was unable
to completely normalize the AUC. At 5 pM TF and the
same rivaroxaban concentration, an AUC of 60% could
be normalized with 1.2 IU/ml PCC, while at 20 pM TF a
slight reduced AUC (84% of normal) required only
0.2 IU/ml PCC [68]. A similar observation was made for
apixaban [32]. In contrast, in vitro reversal of dabigatran
anticoagulation by PCC appeared TF concentration in-
dependent [32]. For the potential applicable reversal
agents rFVIIa and activated PCC, any TF dependency
remains to be established. The TF concentration de-
pendency in monitoring reversal of rivaroxaban and
apixaban induced anticoagulation by PCC, however,
highlights the need for assay standardization.
There are several other (pre)analytical conditions to
consider. Of potential importance are compositional dif-
ferences between clotting factor concentrates, including
the presence of heparin, that may translate into poor la-
boratory outcome while hemostatically effective [73].
Also the influence of blood cells and platelets on the
PCC dose required for TGA normalization is an issue
that needs further investigation [68].
Specialty tests, a pitfall in the assessment of NOAC reversal
Lack of awareness of the applicability of a certain labora-
tory test in monitoring OAC reversal has led to confus-
ing recommendations. E.g., based on the outcome of the
thrombin time (TT) and ecarin clotting time (ECT) in
the reversal of NOAC anticoagulation by PCC in healthy
volunteers, PCC was discarded as reversal agent for
dabigatran while effective as a hemostatic drug in
dabigatran-anticoagulated animals [73,106,109]. Indeed,
TT and ECT are extremely sensitive to dabigatran antic-
oagulation [86]. However, these tests are insensitive to
anticoagulation reversal by PCC. In the TT test, excess
thrombin is added to a plasma sample, as such overrul-
ing the complete coagulation cascade (see Figure 2). As
a consequence, dabigatran in the plasma sample will
inhibit the added thrombin without being affected by
increased clotting factor levels due to PCC administra-
tion. In the ECT test, all prothrombin in the plasma sam-
ple is converted to thrombin by the addition of the viper
venom Ecarin. The ECT is only sensitive to prothrombin
levels below 60% [110,111], a concentration not to be ex-
pected in NOAC treated individuals. Clotting time in the
ECT test, like in the TT test, is prolonged by dabigatranpresent in the plasma sample, while an increase in vitamin
K-dependent clotting factors upon PCC administration
will be unnoticed. Also the diluted thrombin time, a test
particularly suitable for dabigatran measurements, is not
able to reveal reversal of dabigatran anticoagulation
[73,112]. Similarly, chromogenic anti-Xa assays suited for
rivaroxaban determinations, do not reveal reversal of
anticoagulation by clotting factor concentrates. Global co-
agulation tests, measuring the complete hemostatic poten-
tial of a whole blood or plasma sample, are the only
applicable tests for the determination of anticoagulation
reversal by non-specific prohemostatic agents.
Conclusion
While the global coagulation tests PT and APTT have
been extensively studied for their applicability in measur-
ing VKA as well as NOAC anticoagulation, comprehen-
sive validation studies for TGA and above all for TEG/
TEM are scare. Applicability of a particular test in moni-
toring NOAC or VKA anticoagulation is not translated
directly to applicability in reversal assessment (Table 3).
This review clearly shows that mPT (modified PT), TGA-
lag time and TEG/TEM-R/CT are the most sensitive
Brinkman Thrombosis Journal  (2015) 13:9 Page 12 of 14global assay parameters to assess NOAC anticoagulation.
Although these time-based parameters do reveal VKA-
reversal by PCC, they seem to be not suitable for assessing
NOAC reversal by PCC and activated PCC. TGA-lag time,
on the other hand, may be used to assess NOAC reversal
by rFVIIa. This review also shows the potential usefulness
of the TGA-AUC in monitoring reversal of VKA as well as
NOAC anticoagulation by PCC. Analytical considerations,
among others, are the influence of TF concentration and
the presence of blood cells and platelets on the assay
outcome. The poor sensitivity of current available glo-
bal coagulation assays towards NOACs, together with
an assay reagent- and NOAC concentration dependent
anticoagulation reversal by PCC, explains the reported
controversial data on the clinical usefulness of PCC as
reversal agent for NOAC anticoagulation. As a final
remark: global assays may only be used in animal studies
and in clinical practice after extensive in vitro validation,
an approach often neglected.
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